BiotechTube

Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic Emulsion

ApprovedTerminated
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cataract

Conditions

Cataract

Trial Timeline

Dec 1, 2020 → Oct 24, 2022

NCT ID
NCT04687800

About Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic Emulsion

Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic Emulsion is a approved stage product being developed by Ocular Therapeutix for Cataract. The current trial status is terminated. This product is registered under clinical trial identifier NCT04687800. Target conditions include Cataract.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04687800ApprovedTerminated

Competing Products

20 competing products in Cataract

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
52
ISV-305Sun PharmaceuticalPhase 3
77
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
77
Prednisolone acetateNovartisApproved
85
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
80
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
80
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3
72
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
60
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
80
DexycuEyePoint PharmaceuticalsPhase 3
72
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
80
DexycuEyePoint PharmaceuticalsPhase 3
72
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
18
Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved
80
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
36
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
72
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
72
OMS302 + OMS302-PE + VehicleOmeros CorporationPhase 1/2
36

Other Products from Ocular Therapeutix

Dextenza + Prednisolone AcetateApproved
80
Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal PulsationApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone AcetateApproved
80
Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%Approved
80
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Approved
80